Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients

Joan How, Kathleen M.E. Gallagher, Yiwen Liu, Ashley DeMato, Katelin Katsis, Rebecca Larson, Mark B. Leick, Donna S. Neuberg, Marcela V. Maus, Gabriela Hobbs

Blood (2021) 138 (Supplement 1): 316.

https://doi.org/10.1182/blood-2021-145657

Published: 2021

Journal Articles

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela Hobbs, Haesook T. Kim, AJ S. Bottoms, Michael T. Byrne, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Zachariah Defilipp, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen

Blood (2021) 138 (Supplement 1): 169.

https://doi.org/10.1182/blood-2021-146330

Published: 2021

Journal Articles

Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19

Orly Leiva, Umberto Campia, Julia Snyder, Briana Barns, Samantha Rizzo, Candrika Khairani, Hanny Al-Samkari, Rebecca Karp Leaf, Rachel P. Rosovsky, Katayoon Goodarzi, Amir T. Fathi, Samuel Z. Goldhaber, Gregory Piazza, Gabriela Hobbs

Blood (2021) 138 (Supplement 1): 1508.

https://doi.org/10.1182/blood-2021-151801

Published: 2021

Journal Articles

High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients

Chi-Joan How, Charlotte McIlwaine Story, Siyang Ren, Donna S. Neuberg, Rachel P. Rosovsky, Gabriela Hobbs, Jean M. Connors

Blood (2021) 138 (Supplement 1): 3632.

https://doi.org/10.1182/blood-2021-148941

Published: 2021

Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2021) 138 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2021-148668

Published: 2021

Journal Articles

Pulmonary Hypertension Is Associated with Poor Outcomes in Patients with Myeloproliferative Neoplasms and Cardiovascular Disease

Orly Leiva, Siyang Ren, Donna S. Neuberg, Ankeet Bhatt, Andrew Jenkins, Rachel P. Rosovsky, Rebecca Karp Leaf, Katayoon Goodarzi, Gabriela Hobbs

Blood (2021) 138 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2021-149799

Published: 2021

Journal Articles

Immune Profiling of Responses to Influenza Vaccination in Patients with Myeloproliferative Neoplasms

Joan How, Petra Bachanova, Maia Pavlovic, Patrick M. Reeves, Gabriela Hobbs

Blood (2021) 138 (Supplement 1): 3631.

https://doi.org/10.1182/blood-2021-153327

Published: 2021

Journal Articles

Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I ( CFI ) in Primary Myelofibrosis (PMF)

Brooke Sadler, Anna D Chorzalska, Dennis M Bonal, Gabe Haller, Alissa Oakes, Max Petersen, Yuchen Liu, Adam Olszewski, John L Reagan, Pamela C Egan, Rabin Niroula, Diana O Treaba, Gabriela Hobbs, Stephen T. Oh, Jorge Di Paola, Joanna E Baxter, Patrycja M Dubielecka

Blood (2021) 138 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2021-154281

Published: 2021

Journal Articles

Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML)

Areej El-Jawahri, MD, Tanya Keenan, MD, Gregory Abel, MD MPH, David P. Steensma, MD, Thomas W. LeBlanc, MD MA, Lara Traeger, PhD, Amir T. Fathi, MD, Daniel J. DeAngelo, MD PhD, Martha Wadleigh, MD, Gabriela Hobbs, MD, Philip C. Amrein, MD, Richard M. Stone, MD, Karen K. Ballen, MD, Yi-Bin Chen, MD, Jennifer S. Temel, MD

Blood (2015) 126 (23): 3310.

https://doi.org/10.1182/blood.V126.23.3310.3310

Published: 2015

Journal Articles

Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit

Tanya Keenan, MD, Thomas W. LeBlanc, MD MA, Lara Traeger, PhD, Harry Vandusen, BS, Gregory A. Abel, MD MPH, David P. Steensma, MD, Amir T. Fathi, MD, Daniel J DeAngelo, MD PhD, Martha Wadleigh, MD, Gabriela Hobbs, MD, Philip C. Amrein, MD, Richard M. Stone, MD, Karen K. Ballen, MD, Yi-Bin Chen, MD, Jennifer S. Temel, MD, Areej El-Jawahri, MD

Blood (2015) 126 (23): 2104.

https://doi.org/10.1182/blood.V126.23.2104.2104

Published: 2015

Journal Articles

Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone

Areej El-Jawahri, MD, Sean F. Heavey, BS, Thomas W. LeBlanc, MD MA, Harry Vandusen, BS, Gregory Abel, MD MPH, David P. Steensma, MD, Lara Traeger, PhD, Amir T. Fathi, MD, Daniel J. DeAngelo, MD PhD, Martha Wadleigh, MD, Gabriela Hobbs, MD, Philip C. Amrein, MD, Richard M. Stone, MD, Karen K. Ballen, MD, Yi-Bin Chen, MD, Jennifer S. Temel, MD

Blood (2015) 126 (23): 2126.

https://doi.org/10.1182/blood.V126.23.2126.2126

Published: 2015

NARROW

Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19

High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Pulmonary Hypertension Is Associated with Poor Outcomes in Patients with Myeloproliferative Neoplasms and Cardiovascular Disease

Immune Profiling of Responses to Influenza Vaccination in Patients with Myeloproliferative Neoplasms

Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I ( CFI ) in Primary Myelofibrosis (PMF)

Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML)

Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit

Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only